castration-resistant prostate cancer

Apalutimide for Prostate Cancer: What to Know
Apalutimide for Prostate Cancer: What to KnowFDA approves apalutamide for castration-resistant prostate cancer.
FDA approves label update for ZytigaFDA has approved label update for abiraterone acetate (Zytiga, Janssen) in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
Upfront chemo: Time to take noticeThe “embarrassment of riches” of therapeutic options for advanced prostate cancer fortunately continues, encouraging us all to strive for lessening the incidence and impact of prostate cancer-specific mortality.
Protein may predict resistance to prostate cancer TxResearchers have come up with a potential blood-based biomarker that can identify men with castration-resistant prostate cancer who are not likely to respond to enzalutamide (XTANDI).
AUA castration-resistant prostate cancer guideline seeks to clarify decision makingThe AUA has released its first-ever clinical practice guideline for castration-resistant prostate cancer, and all urologists who care for men with advanced prostate cancer should familiarize themselves with its contents, said Michael S. Cookson, MD, who presented the new guideline at the AUA annual meeting in San Diego.